An equine herpesvirus type 1 (EHV-1) vector expressing Rift Valley fever virus (RVFV) Gn and Gc induces neutralizing antibodies in sheep

• Published in: Virology journal Vol. 14; no. 1; p. 154
• Main Authors: Said, Abdelrahman, Elmanzalawy, Mona, Ma, Guanggang, Damiani, Armando Mario, Osterrieder, Nikolaus
• Format: Journal Article
• Language: English
• Published: England BioMed Central 14-08-2017; BMC
• Subjects: Antibodies; Artificial chromosomes; Cloning; Coccidioidomycosis; Deoxyribonucleic acid; DNA; Encephalitis; Fever; Gene expression; Genomes; Glycoproteins; Guanylate cyclase; Hepatitis; Immunization; Immunoglobulins; Infections; Influenza; National parks; Proteins; Rift Valley fever; RNA viruses; Sheep; Short Report; Vaccines; Virology; Viruses
• ISSN: 1743-422X; 1743-422X
• DOI: 10.1186/s12985-017-0811-8

Rift Valley fever virus (RVFV) is an arthropod-borne bunyavirus that can cause serious and fatal disease in humans and animals. RVFV is a negative-sense RNA virus of the Phlebovirus genus in the Bunyaviridae family. The main envelope RVFV glycoproteins, Gn and Gc, are encoded on the M segment of RVFV and known inducers of protective immunity. In an attempt to develop a safe and efficacious RVF vaccine, we constructed and tested a vectored equine herpesvirus type 1 (EHV-1) vaccine that expresses RVFV Gn and Gc. The Gn and Gc genes were custom-synthesized after codon optimization and inserted into EHV-1 strain RacH genome. The rH_Gn-Gc recombinant virus grew in cultured cells with kinetics that were comparable to those of the parental virus and stably expressed Gn and Gc. Upon immunization of sheep, the natural host, neutralizing antibodies against RVFV were elicited by rH_Gn-Gc and protective titers reached to 1:320 at day 49 post immunization but not by parental EHV-1, indicating that EHV-1 is a promising vector alternative in the development of a safe marker RVFV vaccine.